WCLC 2025 - Posters & ePosters-EP.08.39 Adjuvant Therapy With Furmonertinib Significantly Reduces the Recurrence Rate in Lung Cancer Patients With Exon 20 Insertion Mutations

EP.08.39 Adjuvant Therapy With Furmonertinib Significantly Reduces the Recurrence Rate in Lung Cancer Patients With Exon 20 Insertion Mutations

Back to course

Pdf Summary

This case series evaluated the efficacy of furmonertinib, a third-generation EGFR tyrosine kinase inhibitor, as adjuvant therapy in five non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion mutations—a rare subtype associated with poor prognosis and limited treatment options. The patients, predominantly female with a median age of 73, all underwent surgery followed by adjuvant furmonertinib; one switched to sunvortinib after one year. Over a median 24-month follow-up, the 2-year disease-free survival rate was 80%, exceeding expectations for this mutation subtype. Only one patient experienced recurrence, developing liver and bone metastases after switching therapy. Adverse events were mild and manageable, including rash and oral ulcers, with no severe toxicities recorded.<br /><br />Pathologically, most patients had stage IIIA lung adenocarcinoma with poorly differentiated tumors and frequent mediastinal lymph node involvement. Additional features included pleural invasion, micropapillary patterns, vascular emboli, and airway spread.<br /><br />While these findings suggest furmonertinib may effectively reduce recurrence in this high-risk group, the study's retrospective design, small sample size, and limited follow-up highlight the need for prospective trials to confirm long-term efficacy and safety. Future research should explore combination approaches with other targeted agents or immunotherapies to improve outcomes further. Additionally, developing predictive biomarkers is critical to identify patients most likely to benefit, facilitating personalized treatment strategies. Overall, furmonertinib shows promise as an adjuvant therapy option for NSCLC patients with EGFR exon 20 mutations, warranting further investigation.

Asset Subtitle

Jialu Chen

Meta Tag

Speaker Jialu Chen

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

furmonertinib

EGFR exon 20 insertion mutations

non-small cell lung cancer

adjuvant therapy

third-generation EGFR tyrosine kinase inhibitor

disease-free survival

lung adenocarcinoma

recurrence

targeted therapy

predictive biomarkers